Form 4 for IBIO iBio, Inc.
Accepted 2022-11-15 00:00:00 ET · period of report 2022-11-11 · accession 0001104659-22-118975 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-15 | 2022-11-11 | IBIO | Lutz Robert Matthew | See Remarks | A - Grant | $0.00 | +100.1K | 102.2K | +4,747% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-11 | A | A | 100,057 | $0.00 | 102,165 | D | — | — | (F1) Consists of 100,057 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 100,057 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 100,057 RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Corporation's 2023 objectives, as defined by the Board of Directors. |